CD8A and neoplasm: Enriched CD8+ TCM confers a potent in vivo antitumor immune response leading to sustaining long-term tumor regression in melanoma model.32 From day 14–28 after the treatment, TSCM was increased, and CD8+ T cells displayed a phenotype of self-renewing memory T cells from day 21–90, suggesting that the majority of memory CD8+ T cells was likely TSCM to ensure durable protection against tumor.